Physician profile
Boris Reydel
NPI 1457394124
$1,005.40
in general payments reported to CMS, 2019-2025
8 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2021: $15.34 · 2022: $13.83 · 2023: $12.78 · 2024: $290 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Incorporated | $499.10 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $275.44 | 2024 | Dat Device |
| Qol Medical, LLC | $82.37 | 2024-2025 | Sucraid, Sucraid |
| Pentax of America, INC. | $60.31 | 2021-2025 | Pentax Medical, C2 Cryoballoon, C2 Cryoballoon Focal Controller |
| Ardelyx, INC. | $32.94 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.61 | 2022-2023 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2025 | Eohilia |
| Ferring Pharmaceuticals INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Reydel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.